title: [Perspectives on postgenome medicine: Gene therapy for brain tumors].
abstract: Recent development of therapeutic modalities in neurosurgery has brought about dramatic improvement for prognosis of brain tumors. Nevertheless, malignant glioma is one of the most formidable neoplasms in humans. According to a report by the Committee of Brain Tumor Registry of Japan, five-year relative survival rate of malignant gliomas is less than 10%. Malignant gliomas grow aggressively infiltrating into the surrounding normal brain tissue. So that total surgical resection is impossible. The tumors respond to radiation and chemotherapy, however, the efficiency has sustained transiently. The advert of new strategies for the treatment of malignant gliomas has long been awaited. We have developed a cytokine gene therapy for malignant glioma since about 10 years ago. Here, we introduce both suicide gene therapies and immune gene therapies including our case(IFN-beta gene therapy).
authors.affiliation: Department of Molecular Neurosurgery, Nagoya University, Graduate School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Mizuno
authors.forename: J
authors.initials: J
authors.lastname: Yoshida
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics / Q000628:therapy*; D016207:Cytokines / Q000235:genetics; D015774:Ganciclovir / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D015894:Genome, Human; D023281:Genomics; D005910:Glioma / Q000235:genetics / Q000628:therapy*; D016045:Human Genome Project; D006801:Humans; D011355:Prodrugs / Q000627:therapeutic use; D018139:Simplexvirus / Q000201:enzymology; D013937:Thymidine Kinase / Q000235:genetics
chemical_list: D016207:Cytokines; D011355:Prodrugs; D013937:Thymidine Kinase; D015774:Ganciclovir